South Plainfield-based PTC Therapeutics Inc. announced Monday that Chief Operating Officer Marcio Souza resigned and will leave the company by April 25.
Chief Executive Officer Stuart Peltz said Marcio started with PTC more than six years ago and has been instrumental in helping transform the company.
“While Marcio has been at PTC, we have grown from a U.S. based R&D organization about to launch its first treatment, to a fully integrated global company with three commercial products and a rich pipeline of many other potential treatments for multiple rare disorders,” said Chief Executive Officer Stuart Peltz. “I am appreciative of his efforts in helping us grow PTC to the next level and wish Marcio the very best in his new endeavors. While Marcio will be missed, we have a very strong organization with experienced leadership in place and we are well positioned to continue to take PTC into its next stage of development.”
“PTC has always focused on providing innovative and transformative treatments to patients and I am proud to have been part of that mission,” Souza said.
PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders.